Literature DB >> 11967124

Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults.

R Raqib1, F Qadri, P SarkEr, S M S Mia, P J Sansonnetti, M J Albert, J Andersson.   

Abstract

We hypothesized that increased susceptibility to Shigella infection, increased severity of disease and high mortality in children compared with adults were consequences of insufficient adaptive immune responses. Antigen-specific immune responses were studied in paediatric patients (n = 38, 2-10 years) with shigellosis and compared with those of adult patients (n = 30, 18-45 years). Peak frequencies of antigen (invasion plasmid coded antigen B, Ipa-B; lipopolysaccharide, LPS)-specific immunoglobulin (IgM)-antibody secreting cells (ASC) were seen within 3-5 days after the onset of diarrhoea in children, while peak IgA- and IgG-ASCs were obtained 8-10 days later in line with adults. Antigen-specific ASC responses in children ranged between 2 and 4% of the total ASC responses, in contrast to 8-15% in adults. The kinetics of LPS-specific IgG subclass titres was different in younger children (2.5-5 years) (IgG1 > IgG2 > IgG4 > IgG3) compared with in older children (6-8 years) (IgG2 > IgG1 >IgG3 > IgG4) and adults. Secretory IgA levels in stool peaked 8-10 days after onset in both adults and children. However, a rapid induction of stool LPS-specific IgA, IgA1 and IgA2 occurred in adult patients within 3-5 days of onset, while in children, this was delayed by 8-10 days. Similarly, higher number of tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma expressing cells in vitro were seen in adult patients in response to antigens (LPS and Ipa-B) in the acute stage in contrast to paediatric patients. Thus, paediatric patients with shigellosis have reduced and delayed adaptive immune responses compared with adult patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967124     DOI: 10.1046/j.1365-3083.2002.01079.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.

Authors:  Vladimir A Ledov; Marina E Golovina; Anna A Markina; Yuriy A Knirel; Vyacheslav L L'vov; Alexander L Kovalchuk; Petr G Aparin
Journal:  Vaccine       Date:  2019-01-19       Impact factor: 3.641

Review 3.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

4.  Antigen-specific CD8(+) T cells fail to respond to Shigella flexneri.

Authors:  Stephanie P Jehl; Amy M Doling; Kara S Giddings; Armelle Phalipon; Philippe J Sansonetti; Marcia B Goldberg; Michael N Starnbach
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

5.  Shigella impairs T lymphocyte dynamics in vivo.

Authors:  Wilmara Salgado-Pabón; Susanna Celli; Ellen T Arena; Katharina Nothelfer; Pascal Roux; Gernot Sellge; Elisabetta Frigimelica; Philippe Bousso; Philippe J Sansonetti; Armelle Phalipon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-15       Impact factor: 11.205

6.  Persistence of mucosal mast cells and eosinophils in Shigella-infected children.

Authors:  Rubhana Raqib; Pricila Khan Moly; Protim Sarker; Firdausi Qadri; Nurul Haque Alam; Minnie Mathan; Jan Andersson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 7.  Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.

Authors:  Dani Cohen; Shiri Meron-Sudai; Anya Bialik; Valeria Asato; Sophy Goren; Ortal Ariel-Cohen; Arava Reizis; Amit Hochberg; Shai Ashkenazi
Journal:  Hum Vaccin Immunother       Date:  2019-05-09       Impact factor: 3.452

8.  Comparison of two major forms of the Shigella virulence plasmid pINV: positive selection is a major force driving the divergence.

Authors:  Ruiting Lan; Gordon Stevenson; Peter R Reeves
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Broadly protective Shigella vaccine based on type III secretion apparatus proteins.

Authors:  Francisco J Martinez-Becerra; Julian M Kissmann; Jovita Diaz-McNair; Shyamal P Choudhari; Amy M Quick; Gabriela Mellado-Sanchez; John D Clements; Marcela F Pasetti; Wendy L Picking
Journal:  Infect Immun       Date:  2011-12-27       Impact factor: 3.441

10.  Differential host immune responses to epidemic and endemic strains of Shigella dysenteriae type I.

Authors:  Mohammad Abu Sayem; Shaikh Meshbahuddin Ahmad; Rokeya Sultana Rekha; Protim Sarker; Birgitta Agerberth; Kaisar Ali Talukder; Rubhana Raqib
Journal:  J Health Popul Nutr       Date:  2011-10       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.